Hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS): Management with l-ornithine-l-aspartate and stent reduction

[1]  S. Saab,et al.  TIPS versus paracentesis for cirrhotic patients with refractory ascites. , 2006, The Cochrane database of systematic reviews.

[2]  A. Nicolini,et al.  Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites , 2004, Hepatology.

[3]  R. Butterworth,et al.  Increased brain serotonin turnover correlates with the degree of shunting and hyperammonemia in rats following variable portal vein stenosis. , 2004, Journal of hepatology.

[4]  W. Hop,et al.  Transjugular intrahepatic portosystemic shunts: long-term patency and clinical results in a patient cohort observed for 3-9 years. , 2004, Radiology.

[5]  L. Gluud,et al.  Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials , 2004, BMJ : British Medical Journal.

[6]  H. Schrem,et al.  Review: Surgical Shunts and Encephalopathy , 2001, Metabolic Brain Disease.

[7]  R. Butterworth,et al.  L-Ornithine-L-Aspartate in Experimental Portal-Systemic Encephalopathy: Therapeutic Efficacy and Mechanism of Action , 1998, Metabolic Brain Disease.

[8]  K. Ahrar,et al.  TIPS-related hepatic encephalopathy: management options with novel endovascular techniques. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.

[9]  K. Reddy,et al.  The North American Study for the Treatment of Refractory Ascites. , 2003, Gastroenterology.

[10]  P. Kamath,et al.  Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. , 2003, Gastroenterology.

[11]  P. Hayes,et al.  Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS , 2002, Hepatology.

[12]  A. Lockwood,et al.  Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998 , 2002, Hepatology.

[13]  Eter,et al.  A COMPARISON OF PARACENTESIS AND TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTING IN PATIENTS WITH ASCITES , 2000 .

[14]  R. Butterworth,et al.  L‐Ornithine‐L‐aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure , 1999, Hepatology.

[15]  R. Butterworth,et al.  Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. , 1999, Gastroenterology.

[16]  G. D’Amico,et al.  TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. , 1999, Radiology.

[17]  David C. Jones,et al.  Breakdown of tolerance to pyruvate dehydrogenase complex in experimental autoimmune cholangitis: A mouse model of primary biliary cirrhosis , 1999, Hepatology.

[18]  P. Malfertheiner,et al.  Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. , 1998, Journal of hepatology.

[19]  A. Blei,et al.  Stenosis of a portacaval anastomosis affects circadian locomotor activity in the rat: a multivariable analysis. , 1997, American journal of physiology. Gastrointestinal and liver physiology.

[20]  G. Kircheis,et al.  Therapeutic efficacy of L‐ornithine‐L‐aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo‐controlled, double‐blind study , 1997, Hepatology.

[21]  V. Vilgrain,et al.  Transjugular intrahepatic portosystemic shunts: Comparison with paracentesis in patients with cirrhosis and refractory ascites: A randomized trial , 1996 .

[22]  V. Vilgrain,et al.  Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. , 1996, Journal of hepatology.

[23]  M. Sherman,et al.  Transjugular Intrahepatic Portosystemic Stent Shunt: Effects on Hemodynamics and Sodium Homeostasis in Cirrhosis and Refractory Ascites , 1995, Annals of Internal Medicine.

[24]  M. Langer,et al.  The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. , 1995, The New England journal of medicine.

[25]  J. Prieto,et al.  Transjugular intrahepatic portal‐systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral, and hemodynamic parameters , 1995, Hepatology.

[26]  J. Roberts,et al.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. , 1995, The American journal of gastroenterology.

[27]  B. Sangro,et al.  Transjugular intrahepatic portal‐systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral, and hemodynamic parameters , 1995, Hepatology.

[28]  M. Langer,et al.  The reducing stent: treatment for transjugular intrahepatic portosystemic shunt-induced refractory hepatic encephalopathy and liver failure. , 1995, Radiology.

[29]  R. Butterworth,et al.  Ammonia‐induced brain edema and intracranial hypertension in rats after portacaval anastomosis , 1994, Hepatology.

[30]  L. Seeff,et al.  Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. , 1977, Gastroenterology.

[31]  H. Leonhardt,et al.  [Therapy of severe hyperammonemia]. , 1972, Medizinische Klinik.